Onxeo er et selskab med speciale i udvikling af lægemidler til behandling af sjældne kræftsygdomme, et område hvor selskabet ser et udækket behandlingsbehov. Onxeo er primærnoteret på Euronext Paris, og er per 1. august navnet på det fusionerede selskab mellem BioAlliance Pharma SA og Topotarget A/S. Fusionen indtraf 22. juli, 2014.
Carsten Borring, chef for Notering og Selskaber, NASDAQ OMX København siger: “Vi er glade for at kunne byde Onxeo velkommen på NASDAQ OMX København, hvor danske investorer kan forblive aktionærer i det fortsatte selskab, og hvor nye investorer får mulighed for at tage del i det nye selskabs udvikling. Vi er stolte over at Onxeo ser værdien i at være børsnoteret på en dansk fondsbørs, og vi ser frem til at kunne tilbyde selskabet den likviditet og synlighed, som en børsnotering på en international markedsplads kan give.”
About NASDAQ OMX Group
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,200 listed companies with a market value of over $8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.
Cautionary Note Regarding Forward-Looking Statements
Information set forth in this communication contains forward-looking statements that involve a number of risks and uncertainties. NASDAQ OMX cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such forward-looking statements include, but are not limited to, statements about our capital return initiatives. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX’s control. These factors include, but are not limited to, NASDAQ OMX’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors detailed in NASDAQ OMX’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on NASDAQ OMX’s website at http://www.nasdaqomx.com and the SEC’s website at www.sec.gov. NASDAQ OMX undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
|
+ Pressekontakt: + Javier Lopez Garrido + 45 3377 0430 + Javier.lopez@nasdaqomx.com |
|
